Glenmark Pharmaceuticals plans to launch phase 1 trial in solid tumors

This article was originally published here

The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CANscript platform. GBR 1342 is based on Glenmark’s proprietary BEAT® platform

The post Glenmark Pharmaceuticals plans to launch phase 1 trial in solid tumors appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply